SuperworthKailera Therapeutics EPS KLRA
Diluted earnings per share by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$1.09
Kailera Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$1.09.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$1.09 | n/a | |
| Q1 FY26 | −$3650.00 | n/a | |
| Q2 FY25 | −$28947.00 | n/a | |
| Q1 FY25 | −$17983.00 | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Kailera Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KLRAKailera Therapeutics | n/m | |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| OMEROmeros | $1.52 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| NRIXNurix Therapeutics | $2.31 | |
| ABUSArbutus Biopharma | $0.78 | |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Kailera Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.